Chardan Capital Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $27

Benzinga Newsdesk www.benzinga.com Positive 54.1%

Neg 0% Neu 0% Pos 54.1%

Chardan Capital analyst Gautam Chukka initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Buy rating and announces Price Target of $27.